Bionomics Ltd - Product Pipeline Review

Global Markets Direct’s, ‘Bionomics Ltd - Product Pipeline Review - 2016’, provides an overview of the Bionomics Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Bionomics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Bionomics Ltd

The report provides overview of Bionomics Ltd including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Bionomics Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Bionomics Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Bionomics Ltd’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Bionomics Ltd

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Bionomics Ltd’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Bionomics Ltd ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Bionomics Ltd Snapshot 6

Bionomics Ltd Overview 6

Key Facts 6

Bionomics Ltd - Research and Development Overview 7

Key Therapeutic Areas 7

Bionomics Ltd - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Bionomics Ltd - Pipeline Products Glance 14

Bionomics Ltd - Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

Bionomics Ltd - Early Stage Pipeline Products 16

IND/CTA Filed Products/Combination Treatment Modalities 16

Preclinical Products/Combination Treatment Modalities 17

Bionomics Ltd - Drug Profiles 18

BL-011256 - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

BNC-101 - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

BNC-105 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

BNC-164 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

BNC-210 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

BNC-420 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Drug for Dyskinesia - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Drug for Pain - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Drugs for Solid Tumors - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Drugs to Inhibit MELK for Solid Tumors - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Bionomics Ltd - Pipeline Analysis 39

Bionomics Ltd - Pipeline Products by Target 39

Bionomics Ltd - Pipeline Products by Route of Administration 40

Bionomics Ltd - Pipeline Products by Molecule Type 41

Bionomics Ltd - Pipeline Products by Mechanism of Action 42

Bionomics Ltd - Dormant Projects 43

Bionomics Ltd - Discontinued Pipeline Products 44

Discontinued Pipeline Product Profiles 44

Drug to Inhibit RET Kinase for Lung and Thyroid Cancer 44

Bionomics Ltd - Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Tables

List of Tables

Bionomics Ltd, Key Facts 6

Bionomics Ltd - Pipeline by Indication, 2016 8

Bionomics Ltd - Pipeline by Stage of Development, 2016 10

Bionomics ...

List of Tables

Bionomics Ltd, Key Facts 6

Bionomics Ltd - Pipeline by Indication, 2016 8

Bionomics Ltd - Pipeline by Stage of Development, 2016 10

Bionomics Ltd - Monotherapy Products in Pipeline, 2016 11

Bionomics Ltd - Out-Licensed Products in Pipeline, 2016 12

Bionomics Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 13

Bionomics Ltd - Phase II, 2016 14

Bionomics Ltd - Phase I, 2016 15

Bionomics Ltd - IND/CTA Filed, 2016 16

Bionomics Ltd - Preclinical, 2016 17

Bionomics Ltd - Pipeline by Target, 2016 39

Bionomics Ltd - Pipeline by Route of Administration, 2016 40

Bionomics Ltd - Pipeline by Molecule Type, 2016 41

Bionomics Ltd - Pipeline Products by Mechanism of Action, 2016 42

Bionomics Ltd - Dormant Developmental Projects,2016 43

Bionomics Ltd - Discontinued Pipeline Products, 2016 44

Bionomics Ltd, Subsidiaries 45

List of Figures

List of Figures

Bionomics Ltd - Pipeline by Top 10 Indication, 2016 8

Bionomics Ltd - Pipeline by Stage of Development, 2016 10

Bionomics Ltd - Monotherapy Products ...

List of Figures

Bionomics Ltd - Pipeline by Top 10 Indication, 2016 8

Bionomics Ltd - Pipeline by Stage of Development, 2016 10

Bionomics Ltd - Monotherapy Products in Pipeline, 2016 11

Bionomics Ltd - Pipeline by Target, 2016 39

Bionomics Ltd - Pipeline by Route of Administration, 2016 40

Bionomics Ltd - Pipeline by Molecule Type, 2016 41

Bionomics Ltd - Pipeline Products by Mechanism of Action, 2016 42

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports